Oxytocin at Elective Cesarean Deliveries: A Dose-finding Study in Women With Twin Pregnancy
Postpartum Hemorrhage, Twin
About this trial
This is an interventional treatment trial for Postpartum Hemorrhage focused on measuring pregnancy, twin, postpartum hemorrhage, oxytocin, Cesarean delivery
Eligibility Criteria
Inclusion Criteria:
- Twin pregnancy
- Elective cesarean delivery under regional anesthesia
- Gestational age ≥36 weeks
- No known additional risk factors for postpartum hemorrhage
- Written informed consent to participate in this study
Exclusion Criteria:
- Refusal to give written informed consent
- Allergy or hypersensitivity to oxytocin
- Conditions that may predispose to uterine atony and postpartum hemorrhage such as placenta previa, severe preeclampsia (as defined by SOGC guidelines (25)), polyhydramnios, uterine fibroids, previous history of uterine atony resulting in PPH, or bleeding diathesis and obesity, defined as pre-pregnancy BMI >40
- Hepatic, renal, and vascular disease
- Use of general anesthesia prior to the administration of the study drug
Sites / Locations
- Mount Sinai Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Oxytocin 0.5IU
Oxytocin 1IU
Oxytocin 2IU
Oxytocin 3IU
Oxytocin 4IU
Oxytocin 5IU
Patient is given 0.5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
Patient is given 1IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
Patient is given 2IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
Patient is given 3IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
Patient is given 4IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.
Patient is given 5IU of oxytocin intravenously over 1 minute, immediately upon delivery of the fetal head.